Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting [Yahoo! Finance]
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
Prelude Therapeutics (PRLD) had its price target raised by Citizens Jmp from $3.00 to $6.00. They now have a "market outperform" rating on the stock.
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 [Yahoo! Finance]
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026